KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Leases (2019 - 2025)

Historic Current Leases for Xenon Pharmaceuticals (XENE) over the last 7 years, with Q3 2025 value amounting to $1.5 million.

  • Xenon Pharmaceuticals' Current Leases rose 778.66% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 778.66%. This contributed to the annual value of $1.4 million for FY2024, which is 538.88% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Current Leases stood at $1.5 million for Q3 2025, which was up 778.66% from $1.5 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Current Leases' 5-year high stood at $1.5 million during Q3 2025, with a 5-year trough of $270000.0 in Q1 2021.
  • Moreover, its 5-year median value for Current Leases was $1.3 million (2023), whereas its average is $1.1 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Current Leases plummeted by 1933.88% in 2022 and then soared by 16618.85% in 2023.
  • Xenon Pharmaceuticals' Current Leases (Quarter) stood at $605000.0 in 2021, then decreased by 19.34% to $488000.0 in 2022, then skyrocketed by 166.19% to $1.3 million in 2023, then rose by 5.39% to $1.4 million in 2024, then rose by 9.2% to $1.5 million in 2025.
  • Its Current Leases was $1.5 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.4 million in Q1 2025.